

Supplementary Table S1. Patient characteristics and CVRF targets attainment in the entire APS group and the 2011 – 2015 and 2016 – 2020 APS subgroups*

Parameters	APS entire (n=122)	APS group 2011 – 2015 (n=61)	APS group 2016 – 2020 (n=61)	p – value
Age [mean ± SD]	44.5 ± 11.3	45.1 ± 11.8	43.8 ± 10.8	0.557
Female sex [N, (%)]	83/122 (68.03)	46/61 (75.41)	37/61 (60.66)	0.081
Disease duration [median, (IQR)]	6 (2-15)	9 (3-17)	4 (1-13)	0.043
Primary APS [N, (%)]	74/122 (60.66)	27/61 (44.26)	47/61 (77.05)	0.000
CKD [N, (%)]	5/121 (4.13)	2/61 (3.28)	3/60 (5.00)	0.680
Smoking current [N, (%)]	35/122 (28.69)	22/61 (36.07)	13/61 (21.31)	0.156
Smoking (pack-years) [median, (IQR)]	2.5 (0-20)	4.5 (0-28)	2 (0-10)	0.227
Smoking target yes [N, (%)]	87/122 (71.31)	39/61 (63.93)	48/61 (78.69)	0.072
Exercise (min/week) [median, (IQR)]	0 (0-180)	60 (0-210)	0 (0-150)	0.228
Exercise target yes [N, (%)]	34/109 (31.19)	20/59 (33.90)	14/50 (28.00)	0.508
Obesity [N, (%)]	40/115 (34.78)	21/59 (35.59)	19/56 (33.93)	0.851
BMI (kg/m ²) [mean ±	27.4 (23.9-	28.1 ± 5.6	28 ± 5.6	0.910

SD]	31.6)			
BMI Target yes [N, (%)]	48/115 (41.74)	24/59 (40.68)	24/56 (42.86)	0.813
Waist circumference (cm) [median, (IQR)]	92 (82-100)	92 (84-101)	91.5 (80-100)	0.848
Waist circumference target yes [N, (%)]	33/109 (30.28)	13/59 (22.03)	20/50 (40.00)	0.042
Hypertension [N, (%)]	45/118 (38.14)	24/61 (39.34)	21/57 (36.84)	0.780
SBP (mmHg) [median, (IQR)]	122 (114-131)	123 (115-131)	121 (112-130)	0.372
DBP (mmHg) [median, (IQR)]	74 (69-80)	75 (68-80)	73.5 (70-80)	0.608
BP Target yes [N, (%)]	100/116 (86.21)	52/61 (85.25)	48/55 (87.27)	0.752
BP Target yes, on anti-hypertensive treatment [N, (%)]	26/32 (81.25)	14/16 (87.50)	12/16 (75.00)	0.654
BP target yes, without anti-hypertensive treatment [N, (%)]	74/84 (88.10)	38/45 (84.44)	36/39 (92.31)	0.267
Antihypertensives, current use [N, (%)]	34/122 (27.87)	16/61 (26.23)	18/61 (29.51)	0.690
Dyslipidaemia [N, (%)]	28/112 (25.00)	12/60 (20.00)	16/52 (30.77)	0.189
Cholesterol (mg/dl) [mean \pm SD]	179 (156-206)	188.35 \pm 40.6	181.1 \pm 34.4	0.307

LDL (mg/dl) [median, (IQR)]	102 (82-130)	107 (87-138)	95 (80-126)	0.047
LDL Target yes [N, (%)]	57/109 (52.29)	26/58 (44.83)	31/51 (60.78)	0.096
LDL Target yes, on lipid-lowering treatment [N, (%)]	6/19 (31.58)	2/6 (33.33)	4/13 (30.77)	1.000
LDL Target yes, without lipid-lowering treatment [N, (%)]	51/90 (56.67)	24/52 (46.15)	27/38 (71.05)	0.019
HDL (mg/dl) [median, (IQR)]	52 (42-67)	51.5 (40-62)	53.5 (44.5-71)	0.374
HDL Target yes [N, (%)]	80/110 (72.73)	39/58 (67.24)	41/52 (78.85)	0.172
HDL Target yes, on lipid-lowering treatment [N, (%)]	14/19 (73.68)	4/6 (66.67)	10/13 (76.92)	1.000
HDL Target yes, without lipid-lowering treatment [N, (%)]	66/101 (65.34)	35/52 (67.31)	31/49 (79.49)	0.198
Triglycerides (mg/dl) [median, (IQR)]	96 (72-135)	96 (68-132)	98 (74-135)	0.390
Triglycerides target yes [N, (%)]	93/112 (83.04)	50/59 (84.75)	43/53 (81.13)	0.611
Triglycerides Target yes, on lipid-lowering treatment [N, (%)]	13/19 (68.42)	4/6 (66.67)	9/13 (69.23)	1.000

Triglycerides Target yes, without lipid- lowering treatment [N, (%)]	80/93 (86.02)	46/53 (86.79)	34/40 (85.00)	0.805
Lipid-lowering medication, current use [N, (%)]	20/122 (16.39)	7/61 (11.48)	13/61 (21.31)	0.142
Hydroxychloroquine, current use [N, (%)]	53/121 (43.80)	23/61 (37.70)	30/60 (50.00)	0.173
Three-factors target yes [N, (%)]	27/122 (22.13)	17/61 (27.87)	10/61 (16.39)	0.127
Four-factors target yes [N, (%)]	25/122 (20.49)	10/61 (16.39)	15/61 (24.59)	0.262
Five-factors target yes [N, (%)]	29/122 (23.77)	13/61 (21.31)	16/61 (26.23)	0.523

CVRF: cardiovascular risk factor; CKD: Chronic kidney disease; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BP: Blood pressure, LDL: Low density lipoprotein, HDL: High density lipoprotein

There are missing data in some CVRFs; the denominator is the total number of available values for each CVRF.

*p-values refer to the comparison between APS group 2011-2015 vs APS group 2016-2020

Supplementary Table S2. Patient characteristics and CVRF targets attainment in the 2011 – 2015 APS and age and sex – matched RA subgroups comparison.

Parameters	APS group 2011 –	Matched RA patients	p – value
------------	------------------	---------------------	-----------

	2015 (n=61)	(n=61)	
Age [mean \pm SD]	45.1 \pm 11.8	45.4 \pm 11.5	0.891
Female sex [N, (%)]	46/61 (75.41)	46/61 (75.41)	1.000
Disease duration [median, (IQR)]	9 (3-17)	7 (3-16)	0.888
CKD [N, (%)]	2/61 (3.28)	0/59 (0.00)	0.496
Smoking current [N, (%)]	22/61 (36.07)	10/61 (16.39)	0.032
Smoking (pack-years) [median, (IQR)]	4.5 (0-28)	0 (0-8.75)	0.005
Smoking target yes [N, (%)]	39/61 (63.93)	51/61 (83.61)	0.014
Exercise (min/week) [median, (IQR)]	60 (0-210)	0 (0-120)	0.077
Exercise target yes [N, (%)]	20/59 (33.90)	14/61 (22.95)	0.183
Obesity [N, (%)]	21/59 (35.59)	16/61 (26.23)	0.267
BMI (kg/m ²) [mean \pm SD]	28.1 \pm 5.6	26.5 \pm 4.3	0.080
BMI Target yes [N, (%)]	24/59 (40.68)	23/61 (37.70)	0.739
Waist circumference (cm)	92 (84-101)	87 (77-94)	0.041

[median, (IQR)]			
Waist circumference target yes [N, (%)]	13/59 (22.03)	28/61 (45.90)	0.006
Hypertension [N, (%)]	24/61 (39.34)	20/61 (32.79)	0.451
SBP (mmHg) [median, (IQR)]	123 (115-131)	127 (120-137)	0.086
DBP (mmHg) [median, (IQR)]	75 (68-80)	82 (75-85)	0.000
BP Target yes [N, (%)]	52/61 (85.25)	49/61 (80.33)	0.472
BP Target yes, on anti-hypertensive treatment [N, (%)]	14/16 (87.50)	6/12 (50.00)	0.044
BP target yes, without anti-hypertensive treatment [N, (%)]	38/45 (84.44)	43/49 (87.76)	0.642
Antihypertensives, current use [N, (%)]	16/61 (26.23)	12/61 (19.67)	0.389
Dyslipidaemia [N, (%)]	12/60 (20.00)	13/61 (21.31)	0.859
Cholesterol (mg/dl) [median, (IQR)]	181.5 (157.5-213.5)	215 (161-247)	0.037
LDL (mg/dl) [mean]	114.3 ± 35.2	120.3 ± 37.4	0.370

± SD]			
LDL Target yes [N, (%)]	26/58 (44.83)	23/61 (37.70)	0.430
LDL Target yes, on lipid-lowering treatment [N, (%)]	2/6 (33.33)	1/6 (16.67)	1.000
LDL Target yes, without lipid-lowering treatment [N, (%)]	24/52 (46.15)	22/55 (40.00)	0.520
HDL (mg/dl) [median, (IQR)]	51.5 (40-62)	62 (51-80)	0.001
HDL Target yes [N, (%)]	39/58 (67.24)	57/61 (93.44)	0.000
HDL Target yes, on lipid-lowering treatment [N, (%)]	4/6 (66.67)	6/6 (100.00)	0.455
HDL Target yes, without lipid-lowering treatment [N, (%)]	35/52 (67.31)	51/55 (92.73)	0.001
Triglycerides (mg/dl) [median, (IQR)]	96 (68-132)	77 (66-123)	0.210
Triglycerides target yes [N, (%)]	50/59 (84.75)	52/61 (85.25)	0.939
Triglycerides	4/6 (66.67)	3/6 (50.00)	1.000

Target yes, on lipid-lowering treatment [N, (%)]			
Triglycerides Target yes, without lipid-lowering treatment [N, (%)]	46/53 (86.79)	49/55 (89.09)	0.714
Lipid-lowering medication, current use [N, (%)]	7/61 (11.48)	6/61 (9.84)	0.769
Three-factors target yes [N, (%)]	17/61 (27.87)	15/61 (24.59)	0.681
Four-factors target yes [N, (%)]	10/61 (16.39)	14/61 (22.95)	0.362
Five-factors target yes [N, (%)]	13/61(21.31)	24/61 (39.34)	0.030

CVRF: cardiovascular risk factor; CKD: Chronic kidney disease; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BP: Blood pressure, LDL: Low density lipoprotein, HDL: High density lipoprotein

#There were missing data in some CVRFs; the denominator is the total number of available values for each CVRF.

Supplementary Table S3. Patient characteristics and CVRF targets attainment in the 2011 – 2015 APS and age- and sex – matched DM subgroups.

Parameters	APS group 2011 – 2015	Matched DM patients (n=61)	p – value
------------	-----------------------	----------------------------	-----------

	(n=61)		
Age [mean \pm SD]	45.1 \pm 11.8	44.9 \pm 12.3	0.909
Female sex [N, (%)]	46/61 (75.41)	46/61 (75.41)	1.000
Disease duration [median, (IQR)]	9 (3-17)	10 (5-21)	0.134
CKD [N, (%)]	2/61 (3.28)	4/59 (6.78)	0.435
Smoking current [N, (%)]	22/61 (36.07)	20/61 (32.79)	0.502
Smoking (pack-years) [median, (IQR)]	4.5 (0-28)	0.2 (0-15)	0.192
Smoking target yes [N, (%)]	39/61 (63.93)	41/61 (67.21)	0.703
Exercise (min/week) [median, (IQR)]	60 (0-210)	120 (0-230)	0.316
Exercise target yes [N, (%)]	20/59 (33.90)	24/61 (39.34)	0.536
Obesity [N, (%)]	21/59 (35.59)	22/61 (36.07)	0.957
BMI (kg/m ²) [median, (IQR)]	26.8 (23.9-31.8)	27.8 (23.2-32.9)	0.811
BMI Target yes [N, (%)]	24/59 (40.68)	24/61 (39.34)	0.881
Waist circumference (cm) [median, (IQR)]	92 (84-101)	90 (78-105)	0.765

Waist circumference target yes [N, (%)]	13/59 (22.03)	23/61 (37.70)	0.061
Hypertension [N, (%)]	24/61 (39.34)	22/61 (36.07)	0.709
SBP (mmHg) [median, (IQR)]	123 (115-131)	124 (112-139)	0.896
DBP (mmHg) [median, (IQR)]	75 (68-80)	72 (67-81)	0.743
BP Target yes [N, (%)]	52/61 (85.25)	40/61 (65.57)	0.012
BP Target yes, on anti-hypertensive treatment [N, (%)]	14/16 (87.50)	3/16 (18.75)	0.000
BP target yes, without anti-hypertensive treatment [N, (%)]	38/45 (84.44)	37/45 (82.22)	0.777
Antihypertensives, current use [N, (%)]	16/61 (26.23)	16/61 (26.23)	1.000
Dyslipidaemia [N, (%)]	12/60 (20.00)	31/61 (50.82)	0.000
Cholesterol (mg/dl) [median, (IQR)]	181.5 (157.5-213.5)	185 (166-218)	0.462
LDL (mg/dl) [median, (IQR)]	107 (87-138)	104 (86-137)	0.760

LDL Target yes [N, (%)]	26/58 (44.83)	9/59 (15.25)	0.000
LDL Target yes, on lipid-lowering treatment [N, (%)]	2/6 (33.33)	1/11 (9.09)	0.515
LDL Target yes, without lipid-lowering treatment [N, (%)]	24/52 (46.15)	8/48 (16.67)	0.002
HDL (mg/dl) [median, (IQR)]	51.5 (40-62)	58 (45-67)	0.179
Triglycerides (mg/dl) [median, (IQR)]	96 (68-132)	78 (54-145)	0.225
Triglycerides target yes [N, (%)]	50/59 (84.75)	47/61 (77.05)	0.284
Triglycerides Target yes, on lipid-lowering treatment [N, (%)]	4/6 (66.67)	7/12 (58.33)	1.000
Triglycerides Target yes, without lipid-lowering treatment [N, (%)]	46/53 (86.79)	40/49 (81.63)	0.474
Lipid-lowering medication, current use [N, (%)]	7/61 (11.48)	12/61 (19.67)	0.212

Three-factors target yes [N, (%)]	16/61 (26.23)	16/61 (26.23)	1.000
Four-factors target yes [N, (%)]	12/61 (19.67)	12/61 (19.67)	1.000
Five-factors target yes [N, (%)]	14/61 (22.95)	7/61 (11.48)	0.093

CVRF: cardiovascular risk factor; CKD: Chronic kidney disease; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BP: Blood pressure, LDL: Low density lipoprotein, HDL: High density lipoprotein

#There were missing data in some CVRFs; the denominator is the total number of available values for each CVRF.

Supplementary Table S4. Patient characteristics and CVRF targets attainment in the 2016 – 2020 APS and age- and sex – matched DM subgroups.

Parameters	APS group 2016 – 2020 (n=61)	Matched DM patients (n=61)	p – value
Age [mean ± SD]	43.8 ± 10.8	44.1±11.2	0.918

Female sex [N, (%)]	37/61 (60.66)	37/61 (60.66)	1.000
Disease duration [median, (IQR)]	4 (1-13)	20 (6-25)	0.000
CKD [N, (%)]	3/60 (5.00)	6/57 (10.53)	0.314
Smoking current [N, (%)]	13/61 (21.31)	23/61 (37.70)	0.025
Smoking (pack-years) [median, (IQR)]	2 (0-10)	2.5 (0-15)	0.807
Smoking target yes [N, (%)]	48/61 (78.69)	38/61 (62.30)	0.047
Exercise (min/week) [median, (IQR)]	0 (0-150)	135 (0-230)	0.016
Exercise target yes [N, (%)]	14/50 (28.00)	27/61 (44.26)	0.077
Obesity [N, (%)]	19/56 (33.93)	17/61 (27.87)	0.478
BMI (kg/m ²) [median, (IQR)]	27.9 (23.9-31.5)	25.2 (22.4-26)	0.348
BMI Target yes [N, (%)]	24/56 (42.86)	31/61 (50.82)	0.389
Waist circumference (cm) [median, (IQR)]	91.5 (80-100)	92 (79-101)	0.650
Waist circumference	20/50 (40.00)	28/61 (45.90)	0.532

target yes [N, (%)]			
Hypertension [N, (%)]	21/57 (36.84)	18/61 (29.51)	0.297
SBP (mmHg) [median, (IQR)]	121 (112-130)	119 (112-135)	0.838
DBP (mmHg) [mean \pm SD]	74.9 \pm 7.4	73.2 \pm 7.2	0.195
BP Target yes [N, (%)]	48/55 (87.27)	50/61 (81.97)	0.431
BP Target yes, on anti-hypertensive treatment [N, (%)]	12/16 (75.00)	7/16 (43.75)	0.149
BP target yes, without anti-hypertensive treatment [N, (%)]	36/39 (92.31)	43/45 (95.56)	0.530
Antihypertensives, current use [N, (%)]	18/61 (29.51)	16/61 (26.23)	0.686
Dyslipidaemia [N, (%)]	16/52 (30.77)	30/61 (49.18)	0.047
Cholesterol (mg/dl) [median, (IQR)]	177 (155-201)	174 (166-202)	0.346
LDL (mg/dl) [median, (IQR)]	95 (80-126)	106 (93.5-117)	0.059
LDL Target yes [N, (%)]	31/51 (60.78)	8/60 (13.33)	0.000

LDL Target yes, on lipid-lowering treatment [N, (%)]	4/13 (30.77)	1/16 (6.25)	0.144
LDL Target yes, without lipid-lowering treatment [N, (%)]	27/38 (71.05)	7/44 (15.91)	0.000
HDL (mg/dl) [median, (IQR)]	53.5 (44.5-71)	55.5 (43-64.5)	0.374
Triglycerides (mg/dl) [median, (IQR)]	98 (74-135)	71 (54-103)	0.012
Triglycerides target [N, (%)]	43/53 (81.13)	49/61 (80.33)	0.914
Triglycerides Target yes, on lipid-lowering treatment [N, (%)]	9/13 (69.23)	10/17 (58.82)	0.708
Triglycerides Target yes, without lipid-lowering treatment [N, (%)]	34/40 (85.00)	39/44 (88.64)	0.622
Lipid-lowering medication, current use [N, (%)]	13/61 (21.31)	17/61 (27.87)	0.400
Three-factors target yes [N, (%)]	15/61 (24.59)	19/61 (31.15)	0.419

Four-factors target yes [N, (%)]	20/61 (32.79)	10/61 (16.39)	0.036
Five-factors target yes [N, (%)]	11/61 (18.03)	12/61 (19.67)	0.817

CVRF: cardiovascular risk factor; CKD: Chronic kidney disease; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BP: Blood pressure, LDL: Low density lipoprotein, HDL: High density lipoprotein

#There were missing data in some CVRFs; the denominator is the total number of available values for each CVRF.

Supplementary Table S5. Cardiovascular risk classification (low/moderate, high and very high-risk categories) according to SCORE prediction tool for all patient groups.

Patient groups	Cardiovascular risk categories according to SCORE prediction tool [N, (%)]			p-values
	Low/moderate	High	Very high	
APS entire (n=117)#	90 (76.92)	1 (0.85)	26 (22.22)	-
APS group 2011-2015	50 (83.33)	1 (1.67)	9 (15.00)	

(n=60)#				0.075*
APS group 2016-2020 (n=57)#	40 (70.18)	0 (0.00)	17 (29.82)	
Matched RA patients (n=61)	61 (100)	0 (0.00)	0 (0.00)	0.001**
Matched DM patients for APS group 2011-2015 (n=61)	0 (0.00)	12 (19.67)	49 (80.33)	0.000***
Matched DM patients for APS group 2016-2020 (n=61)	0 (0.00)	13 (21.31)	48 (78.69)	0.000****

SCORE: Systemic Coronary Risk Evaluation

#In 1 of 61 patients of the 2011- 2015 APS subgroup, and in 4 of 61 patients of the 2016-2020 subgroup, there were missing data for at least one of seven CVRFs required for CVD risk classifications according to SCORE.

*p-value refers to the comparison between APS group 2011-2015 vs APS group 2016-2020

** p-value refers to the comparison between APS group 2011-2015 vs matched RA patients

*** p-value refers to the comparison between APS group 2011-2015 vs matched DM patients

*** p-value refers to the comparison between APS group 2016-2020 vs matched DM patients

Supplementary Table S6. CVRF targets attainment in the reclassified entire APS group and the 2011 – 2015 and 2016 – 2020 APS subgroups comparison*.

Parameters	APS entire (n=125)	APS group 2011 – 2015 (n=62)	APS group 2016 – 2020 (n=63)	p – value
Age [mean \pm SD]	44.8 \pm 11.5	45.4 \pm 12	44.2 \pm 11	0.548
Female sex [N, (%)]	85/125	46/62	39/63	0.141

	(68.00)	(74.19)	(61.90)	
Smoking target yes [N, (%)]	90/125 (72.00)	40/62 (64.52)	50/63 (79.37)	0.065
Exercise target yes [N, (%)]	36/112 (32.14)	21/60 (35.00)	15/52 (28.85)	0.487
BMI Target yes [N, (%)]	49/118 (41.53)	24/60 (40.00)	25/58 (43.10)	0.732
Waist circumference target yes [N, (%)]	34/112 (30.36)	13/60 (21.67)	21/52 (40.38)	0.032
BP Target yes [N, (%)]	102/119 (85.71)	52/62 (83.87)	50/57 (87.72)	0.549
BP Target yes, on anti-hypertensive treatment [N, (%)]	26/33 (78.79)	14/17 (82.35)	12/16 (75.00)	0.688
BP target yes, without anti-hypertensive treatment [N, (%)]	76/86 (88.37)	38/45 (84.44)	38/41 (92.68)	0.319
LDL Target yes [N, (%)]	67/112 (59.82)	30/59 (50.85)	37/53 (69.81)	0.041
LDL Target yes, on lipid-lowering treatment [N, (%)]	12/22 (54.55)	4/7 (57.14)	8/15 (53.33)	1.000
LDL Target yes, without lipid-lowering treatment [N, (%)]	55/90 (61.11)	26/52 (50.00)	29/38 (76.32)	0.011
HDL Target yes [N,	81/113	39/59	42/54	0.169

(%)	(71.68)	(66.10)	(77.78)	
HDL Target yes, on lipid-lowering treatment [N, (%)]	15/22 (68.18)	4/7 (57.14)	11/15 (73.33)	0.630
HDL Target yes, without lipid-lowering treatment [N, (%)]	66/91 (72.53)	35/52 (67.31)	31/39 (79.49)	0.198
Triglycerides target yes [N, (%)]	95/115 (82.61)	50/60 (83.33)	45/55 (81.82)	0.830
Triglycerides Target yes, on lipid-lowering treatment [N, (%)]	15/22 (68.18)	4/7 (57.14)	11/15 (73.33)	0.630
Triglycerides Target yes, without lipid-lowering treatment [N, (%)]	80/93 (86.02)	46/53 (86.79)	34/40 (85.00)	0.805
Three-factors target yes [N, (%)]	28/125 (22.40)	18/62 (29.03)	10/63 (15.87)	0.078
Four-factors target yes [N, (%)]	25/125 (20.00)	10/62 (16.13)	15/63 (23.81)	0.283
Five-factors target yes [N, (%)]	31/125 (24.80)	13/62 (20.97)	18/63 (28.57)	0.325

CVRF: cardiovascular risk factor; BMI: Body mass index; BP: Blood pressure,

LDL: Low density lipoprotein, HDL: High density lipoprotein

There were missing data in some CVRFs; the denominator is the total number of available values for each CVRF.

*p-values refer to the comparison between APS group 2011-2015 vs APS group 2016-2020

Supplementary Table S7. CVRF targets attainment in the reclassified 2011 – 2015 APS and age and sex – matched RA subgroups comparison.

Parameters	APS group 2011 – 2015 (n=62)	Matched RA patients (n=62)	p – value
Age [mean ± SD]	45.4 ± 12	45.6 ± 11.5	0.935
Female sex [N, (%)]	46/62 (74.19)	46/62 (74.19)	1.000

Smoking target yes [N, (%)]	40/62 (64.52)	53/62 (85.48)	0.007
Exercise target yes [N, (%)]	21/60 (35.00)	14/62 (22.58)	0.129
BMI Target yes [N, (%)]	24/60 (40.00)	24/62 (38.71)	0.884
Waist circumference target yes [N, (%)]	13/60 (21.67)	29/62 (46.77)	0.004
BP Target yes [N, (%)]	52/62 (83.87)	49/62 (79.03)	0.488
BP Target yes, on anti-hypertensive treatment [N, (%)]	14/17 (82.35)	7/13 (53.85)	0.123
BP target yes, without anti-hypertensive treatment [N, (%)]	38/45 (84.44)	42/49 (85.71)	0.863
LDL Target yes [N, (%)]	30/59 (50.85)	23/62 (37.10)	0.128
LDL Target yes, on lipid-lowering treatment [N, (%)]	4/7 (57.14)	1/7 (14.29)	0.266
LDL Target yes, without lipid-lowering treatment [N, (%)]	26/52 (50.00)	22/55 (40.00)	0.299
HDL Target yes [N, (%)]	39/59 (66.10)	58/62 (93.55)	0.000
HDL Target yes, on	4/7	7/7	0.192

lipid-lowering treatment [N, (%)]	(57.14)	(100.00)	
HDL Target yes, without lipid-lowering treatment [N, (%)]	35/52 (67.31)	51/55 (92.73)	0.001
Triglycerides target yes [N, (%)]	50/60 (83.33)	53/62 (85.48)	0.743
Triglycerides Target yes, on lipid-lowering treatment [N, (%)]	4/7 (57.14)	4/7 (57.14)	1.000
Triglycerides Target yes, without lipid-lowering treatment [N, (%)]	46/53 (86.79)	49/55 (89.09)	0.714
Three-factors target yes [N, (%)]	18/62 (29.03)	15/62 (24.19)	0.542
Four-factors target yes [N, (%)]	10/62 (16.13)	14/62 (22.58)	0.363
Five-factors target yes [N, (%)]	13/62 (20.97)	25/62 (40.32)	0.019

CVRF: cardiovascular risk factor; BMI: Body mass index; BP: Blood pressure,

LDL: Low density lipoprotein, HDL: High density lipoprotein

There were missing data in some CVRFs; the denominator is the total number of available values for each CVRF.